Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

ESSA Pharma Inc. (V:EPI)

Business Focus: Biotechnology & Medical Research

Get the company report for the most recent outlook updated daily
Log in or join to add this stock to your watch list.

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for EPI within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Oct 18, 2019 16:15 ET
ESSA Announces Changes to its Board of Directors
VANCOUVER and HOUSTON, TX, Oct. 18, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announces that Ari Brettman has been appointed to the board of the directors of the Company (the "Board") pursuant to a nomination right granted to Clarus Lifesciences III, L.P., now managed by Blackstone Life Sciences. The Company also announces that Otello Stampacchia, who has represented Omega Funds, has resigned from the Board as he focuses on new investments.  
Read full article
Oct 18, 2019 16:15 ET
ESSA Announces Changes to its Board of Directors
VANCOUVER and HOUSTON, TX, Oct. 18, 2019 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announces that Ari Brettman has been appointed to the board of the directors of the Company (the "Board") pursuant to a nomination right granted to Clarus Lifesciences III, L.P., now managed by Blackstone Life Sciences. The Company also announces that Otello Stampacchia, who has represented Omega Funds, has resigned from the Board as he focuses on new investments.   ...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
2.21
--
--
Price to Sales - TTM
--
12.83
11.16
Price to Book - most recent quarter
48.40
2.27
2.34
Price to Cash Flow per share - TTM
--
--
11.97
Price to Free Cash Flow per share - TTM
--
4.68
18.20
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Sep 30, 20195,626-7,118
Sep 15, 201912,74410,513
Aug 31, 20192,231406
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

ESSA Pharma, Inc. is a Canada-based pharmaceutical company. The Company is focused on developing therapies for the treatment of castration-resistant prostate cancer (CRPC). It is developing EPI-7386 for the treatment of metastatic CRPC (mCRPC). It is also developing EPI-7386 combination therapy for mCRPC. Its pipeline also includes antinen for triple negative androgen receptor (AR+) breast cancer. Its proprietary aniten compounds bind to the N-terminal domain of the androgen receptor (AR), inhibiting ARdriven transcription and the AR signaling pathway in a manner which bypasses the drug resistance mechanisms associated with current anti-androgens.

See business summary

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Twitter

Search (past week) for $EPI.CA EPI.V

  • No tweets found